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Abbreviations used in this document  
 
WHO:  World Health Organisation  
USA:  United States of America 
ASIR:  Age Standardised Incidence Ratio 
MDT:  Multi-disciplinary Team 
SA:  South Africa 
SPSS:   Statistical Program for Social Sciences 
GP:    General Practitioner 
OPD:   Out patients department (clinic setting) 
SOPD:   surgical out patients department 
FNAC:   fine needle aspiration cytology  
WLE:   wide local excision  
CXR:   Chest x-ray 
GDP:    Gross Domestic Product  
USD:    United States Dollar 
 
Glossary of terms used in this document  
 
Patient Delay:  These are delays experienced before engaging 
with the health care system from time of onset 
of symptoms.  
 
Systems Delays:  These are delays experienced after engaging 
with the health care system. Also referred to as 
doctor delays  
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Modified Radical Mastectomy An operation to remove the breast whilst 
preserving the pectoral muscles and up to level 
II nodes (Auchincloss variation)  
Sentinel Lymph Node Biopsy An operation to remove 2 or 3 identified lymph 
nodes using radiolabelled isotope or blue dye 
to assess whether the breast cancer has 
spread to the axilla 
 
Breast Conserving Surgery  An operation to treat breast cancer with 
preservation of a cosmetically acceptable 
breast mound. The tumour with a surrounding 
cuff of normal breast tissue is excised. It 
always requires radiotherapy 
 
Neo-adjuvant Therapy   A form of therapy that occurs before surgery. It 
may include any of chemo, radio, hormonal or 
biologic therapy 
 
Adjuvant Therapy  Any form of therapy that occurs after surgery. It 
may include any of chemo, radio, hormonal or 
biologic therapy 
 
Gross Domestic Product The gross domestic product (GDP) represents 
the total value of all goods and services 
produced over a specific time period often used 










1. Title of study 
System Delays in the management of Malignant Breast Disease 
 
2. Investigators 
E Dalwai, I Buccimazza 
 
3. Introduction 
Malignant breast disease remains a major health concern. It is the most common 
cancer in women worldwide and although more common in industrialized 
countries, the WHO reports increasing breast cancer trends worldwide (1). 
 
The annual incidence rate in the USA is 101 per 100 000(2).  In South Africa the 
overall age standard incidence ratio (ASIR) of breast cancer in 2010 was 25.86 
per 100 000 compared to 25.1 per 100 000 in the previous report (1993-
1995)(3,4). A racial disparity remains between women in South Africa with 
incidence rates in SA Black women at 18.33 per 100 000 which are comparable 
with those reported in developing countries. Incidence rates in SA white women 
are 83.72 per 100 000 which are comparable with rates in industrialized countries 
Rates in SA Indian women are almost double those reported in Bombay, India (3) 
 
In under resourced countries like South Africa the disease initially comes to the 
attention of the general surgeon, usually at secondary level hospitals, where the 
diagnosis is confirmed and initial work-up commenced prior to presentation to the 
multidisciplinary team. In centers of excellence this is a seamless process 
involving radiology, pathology and nuclear medicine.  In the state sector in South 
Africa this process is challenging, as it involves lengthy delays due to shortage of 
specialized staff in the above-mentioned disciplines. 
 
At a secondary level hospital in 2008, it was noted that a considerable system 
delay in the diagnosis and work-up of breast cancer patients existed.  
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This observation was the stimulus for the study: to quantify the delays and use 
the information to improve service delivery in the management of breast cancer. 
 
4. Aims  
 Primary Aim 
Document the time delay and reasons from initial presentation at a secondary 
level hospital to initial assessment at the multi-disciplinary breast clinic at a 
tertiary level hospital. 
 Secondary Aims 
a. Document intervals between specific care steps in breast cancer diagnosis 
and treatment so as to identify unique problems 
b. Propose viable policy changes to decrease delay  
 
5. Patients and Methods   
A retrospective audit of all adult patients with histologically proven malignant 
breast disease referred from R K Khan’s Hospital to the multi-disciplinary breast 
oncology clinic at Inkosi Albert Luthuli Central Hospital between Jan 2008 and 
Jan 2009. Data will be collected from hospital folders at both sites and cross 
referenced with an electronic database at Albert Luthuli Hospital. Data collected 
will include basic demographics along with dates for the initial visit, 
mammograms, tissue sampling, staging investigations and combined breast 
oncology clinic. This allows a total system delay and intermediate delays to be 
calculated. Data will be analysed using SPSS version 15.0 (SPSS Inc., Chicago, 
Ill, USA). Quantitative data including time in days between dates of entry and exit 
from the cohort and between intermediate dates will be summarized using mean, 
standard deviation and range, or median and inter-quartile range as appropriate. 
Sample size is estimated at 50-60 patients for the study period.  
 
6. Exclusion criteria 
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Individuals whose folders cannot be located will be excluded. Those that default 
during work-up will be excluded from the overall analysis. Where it is possible 
they will be included in the relevant subset analysis.  
 
Patients who were admitted for their work-up will be excluded from the formal 
analysis. These patients would complete radiological investigations sooner and 




7. Study Limitations  
The main limitation is the inability to confirm that our patients are being upstaged 
by the delay in their work-up. This would have implications on their treatment and 
prognosis. It was found that patients were not being accurately staged at their 
initial presentation. Therefore, no conclusions can be made on effects of the 
system delay documented in this study.  
 
The sample size is small, and could be seen as a limitation. However, it is a 
descriptive study attempting to identify a trend in a select group of patients.  
 
8. Ethical considerations 
The study has been approved by both the University of Kwazulu Biomedical 
Research Ethics Committee and University of Cape Town Human Research 
Ethics Committee. The electronic data files will be password protected and no 
identifying data will be reported. The investigators are part of the surgical team 
managing the study population ensuring no breach of confidentiality. This study 
has no bearing on clinical management decisions during the duration of the study 
period.   
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1. Introduction and Objectives  
 
Breast Cancer is a common malignancy in South Africa with a reported incidence 
of 1 in 29 (1). The management requires many disciplines working together to 
ensure successful outcomes. In resource poor settings ensuring affordable, 
quality healthcare is a challenge. This literature review serves to gain insights 
into the current literature on health systems delays in breast cancer and whether 
outcomes are affected. Health systems with resource constraints will be of 
specific interest as in South Africa costs are a limiting factor. The international 
literature will be used as a reference point to compare our data.  
 
2. Breast Cancer Treatment  
 
The management of breast cancer has historically been predominantly surgical. 
This has evolved with time to a multi modal treatment approach including 
chemotherapy, radiotherapy and hormonal therapy. The surgical options have 
similarly evolved from modified radical mastectomy and axillary clearances to 
include breast conserving therapy and sentinel lymph node biopsy. The main 
reason for this evolution towards less aggressive surgery has been population 
based screening and identification of early lesions. As management has evolved, 
decision-making has become more complex and the resources required have 
escalated.  
 
The average female with breast cancer would require multiple visits to complete 
her triple assessment consisting of clinical examination, pathological diagnosis 
and radiological imaging (2). Once the diagnosis is confirmed, decisions regarding 
management have to be taken and effected. Delays to surgery or initial treatment 
affect both patients and their treating physicians. After recovery from surgery 
most patients will require adjuvant therapy with 6 cycles of chemotherapy that 
lasts for approximately 5 months. After breast conserving surgery radiotherapy is 
mandatory and will last for 4-6 weeks. Radiotherapy may also be offered to 
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patients with a high risk of local recurrence, irrespective of the type of surgery 
performed. Thereafter, females that have estrogen receptor positive tumours will 
require hormonal therapy for 5 years (3). Younger patients may consider risk-
reducing surgery in the form of bilateral oophorectomies to induce menopause. 
The treatment program is often individualised, requires input from various 
disciplines and continues for an extended period of time, which is challenging for 
both our patients and our health systems. 
 
3. Challenges with health systems research 
 
There are a number of challenges when considering health systems research.  
 
3.1 Lack of standardized end-points 
The current literature has varying end-points when determining the delay in 
service delivery (4,5). Most will commence with the first presentation to the health 
service. Some commence from the date of screening mammography, positive 
histology or definitive surgery. Similarly the end-points are scattered between  
a. Confirmed diagnosis of malignancy 
b. Commencement of definitive oncological management 
c. Completion of various oncological treatments 
d. Definitive surgical intervention  
These differences make it difficult to directly compare the current research and 
respective health systems. The main reason for this plethora of standardized end 
points relates to how the data gets collected. These data points are 
retrospectively audited from clerical/ oncology databases explaining the 
variations in reporting.  
 
3.2 Regional Variations 
A further challenge in comparing health systems research is that every country 
has a different health care system making direct comparisons difficult. Similarly 
solutions are not transferable. Variations are also noted within national systems 
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when comparing different districts/provinces. This is a strong argument for 
conducting this type of research.  
 
3.3 Acceptable delay 
There is a lack of evidence supporting an acceptable time delay in the diagnosis 
and work-up of breast malignancy. The suggested timelines, therefore, are 
figures derived from consensus and experience rather than medical evidence. 
The European Guidelines were published in February 2008 in the Annals of 
Oncology and currently recommend the following timelines in working days (6) 
 
 
Defined Care Step  
 
 
Time in working 
days 
Screening mammography and result  15 
Symptomatic mammography and result  5 

















Table 1 European Guidelines for quality assurance in breast cancer – 4th edition 
 
An overall delay of less than 30 working days is recommended from date of 
symptomatic mammogram to date offered for surgery in the case of operable 
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breast cancer. This equates to 6 weeks. The guidelines suggest that “women 
should be fully assessed in three visits or less” and that women with  
“symptoms and signs suggestive of breast cancer must be offered an 
appointment within 2 weeks” (6). This document therefore provides us with a 
benchmark from which to work in the management of breast disease.  
 
4. A case study: The experience in the United Kingdom 
 
The United Kingdom has the fifth largest national economy in the world with a 
gross domestic product of 3.115 trillion USD (7). It is a developed economy with a 
publically funded health care system. In the United Kingdom waiting times in the 
NHS are constantly in the spotlight. In 2000 the NHS Cancer Plan was published 
in which the Labour Government pledged to spend £10 million per annum to 
decrease all cancer waiting lists (8). This document covered the management of 
various regions regarding the management of these diseases. A 2-week rule was 
introduced specifically in the management of breast disease. All patients with 
suspected malignant breast disease had to be seen at a specialist’s clinic within 
2 weeks. A timeline for further work-up of patients or intervention was set at one 
month. This provided a total acceptable time delay of 6 weeks, which are loosely 
based on the European Guidelines, listed above.  
 
Many audits assessed the impact of this newly adopted protocol in an attempt to 
either justify or vilify the guidelines. The Yorkshire Cancer Registry is a large 
database that serves the north of England. The data from 1976–1995 are listed 
below and show average delays well within the guidelines (9). 
 
Delays  Time in days 
Family physician to first hospital visit 10.25 
First hospital visit to first treatment 9.25 
Family physician to first treatment 23.5 
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Table 2. Yorkshire Cancer Registry 1976-1995 (9) 
 
Although certain areas were already within the goal waiting periods, many 
areas/districts were not within these goals. This is where the new waiting period 
guidelines were successful. The approach to the work-up of cancer had been 
standardized thereby ensuring that everybody has access to the same level of 
care. The guidelines were shown to be imperative in ensuring a certain level of 
care was achieved and maintained.  
 
A follow on from the NHS Cancer Plan 2000 was published in 2007 called the 
Cancer Reform Strategy (10). Further commitments have been made to improve 
the care provided to all patients diagnosed with cancer. The following points 
pertain specifically to breast disease 
1. Extended breast screening to under 50’s 
2. All breast symptoms to be seen in 14 days (not only those suspicious of 
cancer) 
3. Decrease radiotherapy waiting times to less than 31 days 
 
These are further efforts to decrease the delay in the work-up and management 
of breast disease with the ultimate aim of decreasing the mortality associated 
with malignant breast disease. 
 
5. Average Delays 
 
In Table 3 the waiting times are noted for the various papers reviewed. They all 
have different end-points and as such cannot be compared directly. The country 
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Surgery delay – 































et al 2001 (12) 
Naples, Italy 644 System delay – first 
consult to hospital 
admission for surgery 
 
1-3m 422 (65%) 
3-6m 102 (16%) 





Table 3: Summary of delays 
 
It is important to note that most of the research originates from developed 
countries with well-funded health care systems. Healthcare inflation within these 
systems are concerning as they are at rates above inflation. Taxpayers need to 
be convinced that their money is being spent wisely and the healthcare is of a 
sufficient standard. This can be achieved with regular audits of the existing 
service thereby ensuring best practice and cost effectiveness. 
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Nova Scotia  
Canada 
637 Surgery delay– diagnosis 
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Oncology delay – surgery 
to first therapy 
 









6. Resource constraint settings 
 
South Africa is defined as a middle income, emerging market economy by the 
International Monetary Fund with an estimated gross domestic product of 350 
billion USD for 2013 (7). We have a publically funded health care system that is 
responsible for health care of approximately 80% of the population. Only 18.4 % 
of the population belongs to a medical insurance scheme and access health care 
in the private sector. In 2014/15, 163 billion Rand was spent on public sector 
health care with 162 billion Rand being spent in the private sector. This provides 
insight into the disparity with our current healthcare system (16).   
There is no data on the systems delays in our healthcare network, which makes 
improvements difficult to achieve and confirm. Data on systems delays in similar 
emerging market economies are not universally available. We have included data 
from Nigeria and Kenya, which focuses on the patient delay to presentation with 
breast cancer. Furthermore, we have information on the breast cancer services in 
Asia, Eastern Europe and Central America.  
 
The data from Africa focus only on patient delay to access health care services 
for breast cancer. These were questionnaire based studies conducted at the 
respective tertiary hospitals with patient estimates of delay. Otieno and his 
Kenyan colleagues found that 73.1% of patients presented more than 3 months 
after noticing the breast mass. The majority (24.1%) were reassured that it was 
harmless when consulting medical personnel, while 23.5% felt the mass was not 
a concern as they were painless (17).  Similar findings were shown by Ukwenya 
and his colleagues in Nigeria, who concluded that the delays were due to a 
combination of local beliefs that were not accepting of western treatment and 
inadequate health care (18).  
 
In a recent article, Breast Care in Developing Countries, Agarwal and colleagues 
looked at the breast cancer care in India, Mexico and Croatia (19). While delays 
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were not specifically discussed insights into breast cancer care in resource 
constraint settings were forthcoming.  
 
In India, the majority of patients present with locally advanced or metastatic 
disease with 5-year survival rates between 48 and 62%. There is no population 
based screening system in place and mammography is not easily available or 
affordable. Diagnosis is made on clinical examination alone, with up to 40% of 
patients undergoing an inadequate surgical procedure as treatment for breast 
cancer. Adjuvant radio or chemotherapy is costly, requires multiple treatment 
sessions and has a social stigma attached to it affecting compliance. Breast 
conservation and sentinel lymph node biopsies are offered to less that 1% of all 
patients diagnosed with breast cancer. This is due to the limited availability of 
radiotherapy and nuclear medicine expertise.  
 
Mexico is the eleventh largest economy globally (7), yet has an ever increasing 
gap between the wealthy and the poor. Breast cancer has become the second 
most common female malignancy after cervical cancer and is routinely diagnosed 
a decade earlier than in developed countries. Mexico introduced a screening 
mammography service in the 1990’s with 508 screening units servicing 12 million 
women over the age of 40 years. Further improvements are needed in the 
treatment of these patients as the public hospitals are overwhelmed, with delays 
in diagnosis and management commonplace, causing disease progression.  
 
Croatia is a country of 4.5 million people, which has radically improved its breast 
cancer service over the last 25 years. At that stage 40% of breast cancers were 
locally advanced. This improvement was achieved with a public education 
program, introduction of mammographic screening (including mobile units), 
establishing a centralized Oncology Breast Unit and a Division of Plastic and 
Breast Surgery. Currently almost half of all breast cancers are less than 10mm in 
size with a 5year survival of 89%.  
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One of the countries where data on systems delays is available is Thailand, 
which is classified as a middle income country with a GDP of 373 billion USD (7). 
This compares favourably with South Africa’s economy and serves as a good 
comparator for this study. Poum and colleagues completed a cross-sectional 
questionnaire based study on 180 patients and found a median patient delay of 
12 days and system delay of 21 days (20). These were patient reported time 
frames, which were corroborated with patient records where possible. They found 
an increased system delay in younger patients, those with previous breast 
complaints, lower education and family income levels. A delay of more than 3 
months was noted in 17% of the cohort which compares with quoted European 
data. Thonsukai and colleagues looked at 94 women and found that the systems 
delay was a median of 4 weeks (21). Almost 25% of patients experienced a delay 
of more than 3 months. The factors associated with an increased delay included 
being single and consulting at a peripheral hospital as opposed to the university 
hospital. These factors highlight the need for a unified breast disease awareness 
program and implementation of certain care standards in the management of 
breast cancer.  
 
7. Effects of delay 
One of the main reasons for health systems research is assessing the impact of 
these delays on patients. The perception is that a long delay increases mortality, 
but proving this remains a challenge. 
 
A meta-analysis done by Richards et al in 1999 analysed 87 studies linking delay 
and mortality (22). Their findings suggest that delays of 3-6 months were 
associated with an increased mortality rate. This is the accepted thinking when 
dealing with the work-up of breast disease and any delay longer than six months 
is unacceptable.  
 
A number of smaller studies have showed no survival difference (11, 23). The main 
reason for this anomaly was that these studies were all done retrospectively and 
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medical practitioners would fast track patients with late-stage disease. Hence the 
paradoxical relationship between increased mortality and a shorter delay in these 
studies. 
 
In summary, there are a number of variables that make health systems research 
challenging. It is imperative that we continuously assess our health system to 
ensure an effective and sustainable service. In this manner we will identify 
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Centralised multidisciplinary management of breast cancer occurs in KwaZulu-
Natal, South Africa and requires a diagnostic and staging pathway at the referring 
hospital. Delays in this pathway are unknown. This study, conducted at a 
referring hospital, R K Khan (RKK), quantifies and analyses these delays  
 
Methods 
A retrospective folder review included all patients with breast cancer diagnosed 
at RKK from January 2008 to January 2009. Data extraction included 
demographic data, time to diagnosis and initial staging using a standardised data 
sheet. Specific care steps were identified, namely delays to initial imaging with 
mammography, pathology confirmation, staging workup and eventual referral to a 
centralised breast clinic.  
 
Results 
A total of 45 patients were included with 43 females and 2 males. The average 
age was 56 years (Range 38 – 82 years). The mean individual care step delays 
were 18.3 days to initial imaging, 21.2 days to pathological confirmation, 9.2 days 
to initial staging and 22.7 days to review at the centralised breast clinic. The 
delays were sequential with a mean total delay of 70.1 days or 10 weeks with an 
interquartile range of 48 - 82 days.  
 
Conclusion 
This study confirmed significant delays in the care pathway, which are almost 
double the international recommendations of 6 weeks. Steps to reduce delays at 
all phases have been instituted with specific care step targets leading to the 
establishment of a breast cancer registry with an audit capability. We suggest 
targeting an 8 week period for the work-up and staging of every patient with 
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breast cancer. The establishment of a breast cancer registry and regular audits 
thereof are essential in maintaining care standards and achieving best practice. 
 






In South Africa, breast cancer is the 4th most common cause of death from all 
malignancies.[1] In South Africa, we notice a discrepancy in incidence rates 
between various ethnic/race groups. African women have rates similar to those in 
other developing countries. Caucasian women have rates that are comparable 
with industrialised countries. In women of Indian origin the rates are almost 
double those reported in India.[1] 
 
In most developing countries, including South Africa, breast cancer initially 
comes to the attention of the general surgeon, usually at a secondary level 
hospital, where the diagnosis is confirmed and surgery is performed. An oncology 
opinion is usually sought in the postoperative period. This system is changing 
and multidisciplinary teams (MDTs) are being formed to manage breast cancer. 
These teams involve surgical, oncology, radiology, pathology, nuclear medicine 
and plastics and reconstructive surgery disciplines. The MDTs consider the 
treatment options and patient preference before deciding on appropriate 
management. Such a system has evolved in the Durban Metropole based at 
Inkosi Albert Luthuli Central Hospital (IALCH). This is not an open access breast 
service and requires a diagnostic and staging pathway at the referring hospital. 
This study conducted at a referral hospital, R K Khan (RKK), quantifies and 
analyses these delays. 
 
The primary objective of the study was to quantify the total time delay between 
initial presentation at RKK and eventual review at the multidisciplinary breast 
clinic at IALCH. The secondary objectives were to document the time intervals 
between specific care steps, identify the reasons for these delays and propose 




RKK is a regional hospital and services a population of approximately 1.5 million 
people.[2] Around 60 new breast cancer cases are diagnosed annually in the 
surgery department. A retrospective folder review included patients with 
histologically proven breast cancer seen at RKK and referred to the MDT at 
IALCH from January 2008 to January 2009. Patients were excluded if they were 
admitted for work-up and management or if folders were inaccessible for data 
collection.  
 
Care pathway  
The care pathway timeline is illustrated in Fig.1, which shows the experience of 
the average patient at this referring hospital. The initial consultation was followed 
by a delay to the mammography/ultrasound (D1 – initial imaging delay). At the 
second visit the mammography or ultrasound was reviewed and a biopsy 
performed followed by a delay awaiting histology results (D2 – pathology delay). 
The third visit consisted of confirming these results and booking a metastatic 
work-up including an abdominal ultrasound, chest radiograph and liver function 
tests (D3 – staging delay). Finally, the fourth visit reviewed these investigations 
and a multidisciplinary breast clinic appointment at IALCH was booked (D4 – 
referral delay). This was the best-case scenario, as some patients would require 
repeat biopsy or additional radiological investigations leading to further delays.  
 
Demographic data captured during the folder review included age, gender and 
address. A timeline was generated for each case by capturing dates of the first 
consultation, mammogram, histology report, abdominal ultrasound, chest 
radiograph and IALCH multidisciplinary breast clinic. The individual care step 
delays were quantified and any reasons sought to explain excessive delays were 
noted during the folder review.  
 
Data analysis was conducted using SPSS for Windows, Version 15.0 (Chicago 
SPSS Inc.). Quantitative data including time in days between dates of entry and 
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exit from the cohort and between intermediate dates have been summarised 
using mean delay and interquartile range. 
 
Results 
The cohort included 45 patients with 43 females and 2 males with a mean age of 
56 years. The mean delay, interquartile range and range are illustrated in Table 
1. These delays were sequential with the referral delay being a week longer than 
the others. If we combine all radiology based delays, i.e. D1 and D3, it totals 27.5 
days which is the longest delay and underscores their importance in breast 
cancer services. The pathology delay (D2) was 3 weeks with six patients 
requiring multiple biopsies to confirm the diagnosis. The final phase of delay (D4) 
was referral to the MDT breast clinic, which averaged 22.7 days. This led to a 
mean total delay of 10 weeks with nine patients who waited over 3 months.  
 
Discussion 
This study confirmed significant delays in the care pathway for breast cancer at a 
regional hospital. An appropriate delay remains a challenge to quantify due to 
lack of an evidence base. Current guidelines are derived from consensus 
statements and experience gained largely from well resourced, publicly funded 
health systems in Europe and North America.[3-8] The delays in these studies are 
tabulated in Table 2 and provide some perspective when interpreting our results. 
It is easy to appreciate that none of the studies conform to standardised reporting 
of delays. The average delay was 5 - 6 weeks for most patients, which is half our 
delay. It is important to note that some of the studies do not have full datasets, 
thus preventing direct comparisons. These audits provide an insight into the 
delays in other health systems and serve as guidelines in determining an 
acceptable delay. 
 
The European Guidelines published in February 2008 recommended an overall 
delay of less than 25 working days from date of symptomatic mammogram to 
date offered for surgery in the case of operable breast cancer. This equates to a 
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maximum acceptable delay of 5 weeks. Furthermore, ‘women should be fully 
assessed in three visits or less’ and ‘women with symptoms and signs suggestive 
of breast cancer must be offered an appointment within 2 weeks.’[9] 
 
In 2010, the European Society of Breast Cancer Specialists published an 
updated position statement on quality indicators in the management of breast 
cancer. Their recommendation is a waiting time of less than 6 weeks from initial 
diagnostic visit to definitive treatment. This time frame has to be achieved in at 
least 75% of patients as a minimum standard.[10] 
 
In the UK, waiting times in the National Health Service (NHS) are constantly in 
the spotlight. In 2000, the NHS Cancer Plan was published in which the Labour 
Government pledged to spend £10 million per annum to decrease all cancer 
waiting lists.[11] A 2-week rule was introduced specifically in the management of 
breast cancer. All patients with suspected malignant breast disease had to be 
seen at a specialist clinic within 2 weeks. A timeline for further work-up of 
patients or intervention was set at a further 4 weeks, providing a total delay of 6 
weeks. 
 
A follow on from the NHS Cancer Plan was published in 2007 called the Cancer 
Reform Strategy.[12] Breast screening was extended to ages under 50 years and 
over 70 years with all patients with breast cancer symptoms to be seen within 2 
weeks. These guidelines have been successful in improving waiting times with 
99.2% of patients with breast cancer starting treatment within 1 month of 
diagnosis.[13] 
 
The underlying concerns with these delays are whether it correlates with an 
increased mortality. A meta-analysis by Richards et al.[14] in 1999 analysed 87 
different studies looking at delay and mortality in breast malignancy. Their 
findings suggest that delays exceeding 3 months were associated with an 
increased mortality rate.[14] A more recent article gathered information from the 
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National Cancer Registry in the UK and found a median delay of 22 days from 
diagnosis to treatment. In contrast, they found no difference in mortality in 
patients who waited more than 25 days.[15] 
 
The consensus is that an acceptable delay is less than 6 weeks from first 
presentation to commencement of treatment. In comparison, our service showed 
a 70 day/10 week mean delay. This is difficult to compare with the guidelines 
discussed above as the end points differed. In our study, our patients were seen 
at a MDT breast clinic within 10 weeks, but were no closer to definitive treatment 
by that stage. We did not discuss patient delay from time of symptoms to first 
contact with the health system as we were unable to quantify this accurately. The 
study had further limitations in that it was a single centre review with no 
comparative data and relatively small numbers. 
 
The initial imaging delay (D1) involved accessing a mammogram and/or an 
ultrasound of the breast. At most regional level hospitals in South Africa there are 
limited radiology and mammography services. This study site had a full time 
radiologist reporting on all mammograms, and yet the radiology delay was a 
major concern. The staging delay (D3) included the delay to an abdominal 
ultrasound, chest radiograph and certain blood tests with the rate limiting step 
being the abdominal ultrasound. If we combine these delays (D1 and D3) they 
total 27.5 days, which is the longest delay. The single radiologist has an 
overwhelming workload, contributing to the delay. 
 
The pathology service is a vital component in our breast cancer service, as 
histology remains the mainstay of diagnosis. In certain instances the specimens 
were inadequate and this reflects the experience of the clinician performing the 
biopsy. The surgical clinic was staffed with a variety of medical personnel from 
surgeons, registrars, medical officers and interns. The need to repeat biopsies 
was thought to be a reason for additional delay to diagnosis. . The second 
component of this delay relates to the delay in processing and reporting the 
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specimen at the pathology laboratory, which services the entire province and has 
staff and resource limitations.  
 
Having identified these delays, meetings were arranged with all the major 
stakeholders including the radiology and pathology services. We sensitised them 
to our concerns regarding the delay and welcomed feedback and logistical 
changes to improve the service. All parties were keen to use this research to 
motivate for additional funding and staff and indicated the need for regular audits 
of the service. 
 
In the surgical clinic, a focal liaison was identified that would expedite the 
referrals of all our patients with breast malignancy to the MDT breast clinic. 
Protocols were also agreed upon to minimise unnecessary mammograms, thus 
alleviating the workload on the radiology department. In patients who had 
obviously suspicious mammograms the radiologist would expedite the metastatic 
work-up by doing the abdominal ultrasound at the same time, thereby decreasing 
the delay. 
 
The data suggests that a central, open access breast clinic might be better suited 
to decreasing the delay and improving overall care for these patients. Anecdotal 
evidence exists in the South African setting that this type of service decreases 
delays in the work-up of breast malignancy.  
 
Developing local guidelines 
There are no guidelines regarding acceptable delays for breast cancer in 
resource poor settings. We have attempted to set some norms for acceptable 
delays based on data generated in this review. The recommendations in Table 3 
would need to be achieved in 75% of patients as a minimum standard.  
 
The establishment of a breast cancer registry is essential in ensuring timeous 
management. The registry can be the responsibility of an experienced nurse and 
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the process overseen by a clinician with experience in the management of breast 
cancer. Regular and ongoing audits of the system are imperative to ensure 
minimum standards are achieved. 
 
Conclusion 
Breast cancer remains a major public health concern, testing our health care 
model in South Africa. The discussion around acceptable and attainable system 
delays is important and needs input from all stakeholders responsible for 













D1 Initial imaging delay - awating mammography/ breast ultrasound 
D2 Pathology delay - awaiting histological confirmation of breast malignancy  















Figure 1 – Care pathway timeline illustrating consultations and time delays between care steps during 
















D1 Initial Imaging  
 
18.3 8.5 – 21.75 2 - 81 
D2 Pathology  
 
21.2 14 – 29 7 - 87 
D3 Staging  
 
9.2 1 – 17 1 - 40 
D4 Referral   
 
22.7 10.75 – 32 1 - 49 
 Total Delay 70.1  47.75 – 82.25 32 - 199 
 
 
Table 1: Results of individual care steps and total delay presented as mean delay, 




Table 2 – Summary of delays in various studies. It represents the various reporting 
standards and end points indicating the difficulty in making direct comparisons. 
Legend  
 Shaded blocks indicate no data available for specific delays in those datasets.
The total delay column refers to totals for available datasets and not necessarily
mean delay to treatment/surgery commencement.
 * Montella et al presented the delay in this format ie the percentage of patients
completed within a certain time frame, and did not provide mean delays
 ** Bardell et al only looked at delay to treatment and did not present data on
diagnosis and staging delay
 Olivotto & Poum’ studies looked at time to diagnosis only and provided no data
on staging or treatment delays
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